The white coat effect is not associated with additional increase of target organ damage in true resistant hypertension

Medicina Clinica

Volumn 140, Issue 1, 2013, Pages 1-5

  Figueiredo, Valéria Nasser ^a   Martins, Luiz Cláudio ^a   Boer Martins, Leandro ^a,b   Cabral De Faria, Ana Paula ^a   De Haro Moraes, Carolina ^a   Cardoso Santos, Rodrigo ^a   Nogueira, Armando R ^c   Moreno Jr , Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Cardiovascular and Metabolism Unit   (Brazil)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Left ventricular hypertrophy; Renal dysfunction; Resistant hypertension; White coat effect

Indexed keywords

CREATININE;

ADULT; AGE; ARTICLE; BLOOD PRESSURE VARIABILITY; BODY MASS; CARDIOVASCULAR PARAMETERS; CONTROLLED STUDY; CREATININE CLEARANCE; ECHOCARDIOGRAPHY; FEMALE; GENDER; HEART LEFT VENTRICLE MASS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; RESISTANT HYPERTENSION; WHITE COAT EFFECT;

AGED; ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORING, AMBULATORY; COMBINED MODALITY THERAPY; CREATININE; DIET, SODIUM-RESTRICTED; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; OBESITY; PROGNOSIS; SINGLE-BLIND METHOD; WHITE COAT HYPERTENSION;

EID: 84872113026     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/j.medcli.2012.04.031     Document Type: Article

References (30)

1. D.A. Calhoun, D. Jones, S. Textor, D.C. Goff, T.P. Murphy, and R.D. Toto Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research Hypertension 51 2008 1403 1419
2. E.S. Muxfeldt, K.V. Bloch, A.R. Nogueira, and G.F. Salles Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension Blood Press Monit 8 2003 181 185
3. T.G. Pickering, W. Gerin, and A.R. Schwartz What is the white-coat effect and how should it be measured? Blood Press Monit 7 2002 293 300
4. P. Lantelme, H. Milon, C. Gharib, C. Gayet, and J.O. Fortrat White coat effect and reactivity to stress: cardiovascular and autonomic nervous system responses Hypertension 31 1998 1021 1029
5. P. Gualdiero, J. Niebauer, C. Addison, S.J. Clark, and A.J. Coats Clinical features, anthropometric characteristics, and racial influences on the 'white-coat effect' in a single-centre cohort of 1553 consecutive subjects undergoing routine ambulatory blood pressure monitoring Blood Press Monit 5 2000 53 57
6. K. Buchholz, H. Schachinger, M. Wagner, A.M. Sharma, and H.C. Deter Reduced vagal activity in salt-sensitive subjects during mental challenge Am J Hypertens 16 2003 531 536
7. R.H. Fagard, and V.A. Cornelissen Incidence of cardiovascular events in white-coat, masked and sustained hypertension versus true normotension: a meta-analysis J Hypertens 25 2007 2193 2198
8. I.Z. Ben-Dov, J.D. Kark, J. Mekler, E. Shaked, and M. Bursztyn The white coat phenomenon is benign in referred treated patients: a 14-year ambulatory blood pressure mortality study J Hypertens 26 2008 699 705
9. P.S. Tsai Determinants of the white-coat effect in normotensives and never-treated mild hypertensives Clin Exp Hypertens 25 2003 443 454
10. A.V. Chobanian, G.L. Bakris, H.R. Black, W.C. Cushman, L.A. Green, and J.L. Izzo Jr. The Seventh Report of the Joint National Committee on Prevention, Detection Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572
11. A. Groppelli, S. Omboni, G. Parati, and G. Mancia Evaluation of noninvasive blood pressure monitoring devices Spacelabs 90202 and 90207 versus resting and ambulatory 24-hour intra-arterial blood pressure Hypertension 20 1992 227 232
12. R.M. Lang, M. Bierig, R.B. Devereux, F.A. Flachskampf, E. Foster, and P.A. Pellikka Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
13. M.G. Myers, and R.A. Reeves White coat effect in treated hypertensive patients: sex differences J Hum Hypertens 9 1995 729 733
14. M.A. Brown, M.L. Buddle, and A. Martin Is resistant hypertension really resistant? Am J Hypertens 14 2001 1263 1269
15. R. Hernandez-delRey, P. Armario, M. Martin-Baranera, P. Sanchez, G. Cardenas, and H. Pardell Target-organ damage and cardiovascular risk profile in resistant hypertension. Influence of the white-coat effect Blood Press Monit 3 1998 331 337
16. P. Armario, A. Oliveras, R. Hernandez Del Rey, L.M. Ruilope, and A. De La Sierra Prevalence of target organ damage and metabolic abnormalities in resistant hypertension Med Clin (Barc) 137 2011 435 439
17. K.S. Kristensen, A. Hoegholm, L.E. Bang, P.H. Gustavsen, and C.B. Poulsen No impact of blood pressure variability on microalbuminuria and left ventricular geometry: analysis of daytime variation, diurnal variation and 'white coat' effect Blood Press Monit 6 2001 125 131
18. M.W. Muscholl, H.W. Hense, U. Brockel, A. Doring, G.A. Riegger, and H. Schunkert Changes in left ventricular structure and function in patients with white coat hypertension: cross sectional survey BMJ 317 1998 565 570
19. G. Parati, L. Ulian, L. Sampieri, P. Palatini, A. Villani, and A. Vanasia Attenuation of the "white-coat effect" by antihypertensive treatment and regression of target organ damage Hypertension 35 2000 614 620
20. G.F. Salles, C.R. Cardoso, R. Fiszman, and E.S. Muxfeldt Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension Am Heart J 159 2010 833 840
21. E. Dolan, A. Stanton, L. Thijs, K. Hinedi, N. Atkins, and S. McClory Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study Hypertension 46 2005 156 161
22. L.C. Martins, V.N. Figueiredo, T. Quinaglia, L. Boer-Martins, J.C. Yugar-Toledo, and J.F. Martin Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness J Hum Hypertens 25 2011 532 538
23. P. Palatini, and S. Julius The role of cardiac autonomic function in hypertension and cardiovascular disease Curr Hypertens Rep 11 2009 199 205
24. R. Pedrinelli, G. Dell'Omo, G. Penno, V. Di Bello, D. Giorgi, and G. Pellegrini Microalbuminuria, a parameter independent of metabolic influences in hypertensive men J Hypertens 21 2003 1163 1169
25. R. Nogueira Ada, A.S. Fernandes, E.S. Coutinho, G.F. Salles, E.S. Muxfeld, and K.V. Bloch Factors associated with microalbuminuria in resistant hypertension Int J Cardiol 121 2007 86 87
26. P. Armario, A. Oliveras, R. Hernandez Del Rey, E. Poch, M. Larrouse, and A. Roca-Cusachs Prevalence of target organ damage and factors associated with cardiovascular events in subjects with refractory hypertension Med Clin (Barc) 133 2009 127 131
27. A. Oliveras, P. Armario, R. Hernandez-Del Rey, J.A. Arroyo, E. Poch, and M. Larrousse Urinary albumin excretion is associated with true resistant hypertension J Hum Hypertens 24 2010 27 33
28. R. Minutolo, S. Borrelli, R. Scigliano, V. Bellizzi, P. Chiodini, and B. Cianciaruso Prevalence and clinical correlates of white coat hypertension in chronic kidney disease Nephrol Dial Transplant 22 2007 2217 2223
29. J. Zheng, P. Ye, X. Wang, W.K. Xiao, and H.M. Wu The relationship between obesity and microalbuminuria among general population in Beijing area Zhonghua Nei Ke Za Zhi 50 2011 388 392
30. M. Camafort, and A. Coca Resistant hypertension: beyond a bad control of blood pressure Med Clin (Barc) 137 2011 444 445